What check size does David H. Crean write?

David H. Crean typically writes checks of $250K – $10M.

What boards does David H. Crean sit on?

David H. Crean holds tracked board seats at Histogen.

Where did David H. Crean go to school?

David H. Crean studied at University at Buffalo Pharmacy and Pharmaceutical Sciences (Doctor of Philosophy (Ph.D.), Biophysics); Pepperdine University (Master of Business Administration, Finance); University at Buffalo (Master of Science (M.S.), Natural Sciences / Oncology).

David H. Crean

Investor

Former General Partner at 1004 Venture Partners · Former Venture Partner at VU Venture Partners

San Diego, California

Writes $250K – $10M checks · typically $500K

Find your path to David

532 people in our graph can introduce you to David.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Martín Aspillaga to introduce you to David

You →Martín · together at REF (2024–2026) →David

Ask Jamie Chen to introduce you to David

You →Jamie · together at REF →David

Ask Sam Okafor to introduce you to David

You →Sam · 2 people · together at Phoenix Molecular Designs →David

Your email: the people you already email who know David
2nd- and 3rd-degree connections: people you know who worked, studied or invested with David
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

About

David H. Crean is Managing Partner of Cardiff Advisory LLC, an advisory firm serving life sciences and healthcare companies on mergers and acquisitions, licensing, valuations, and corporate strategy. He serves as Chief Business Officer of MediciNova (NASDAQ: MNOV), leading corporate development, partnering, investor relations, and capital markets strategy, and holds board positions including Chairman of Paracrine Inc. and Lead Independent Director of Cenna Biosciences. Over 30 years in life sciences and capital markets, Crean has advised more than 250 companies and completed more than 50 transactions exceeding $1 billion in aggregate value, with prior roles including Senior Director of Corporate Development at Allergan and Managing Director of Healthcare & Life Sciences at Objective Capital Partners.

Experience

Cardiff Advisory LLCManaging Partnercurrent2021 — presentSan Diego, California
MediciNova, Inc.Chief Business Officer, Head of Investor & Public Relations and Communicationscurrent2021 — presentSan Diego, CA
CEOthreesixty (CEO360,LLC)Co-Founder, Healthcare and Life Sciencescurrent2023 — presentSan Diego, San Francisco, California
BioClarus ConsultingPartnercurrent2026 — presentSan Diego, CA
Snell & WilmerForum Leader - Artificial Intelligence (AI) Leadership Collectivecurrent2025 — presentPalo Alto, CA
REFForum Leader - Life Sciences and Healthcarecurrent2024 — presentSan Diego, California, United States
ConnectMember Board of Directorscurrent2024 — presentSan Diego, California, United States
Paracrine, Inc.Chairman of the Board of Directorscurrent2023 — presentSan Diego, California, United States
Paracrine, Inc.Member Board of Directors2022 — 2023San Diego, California, United States
Biocom CaliforniaBoard of Governor's | Chairman, Capital Development (Partnering & Fundraising)current2022 — presentCalifornia, United States
Cenna BiosciencesMember Board of Directorscurrent2023 — presentSan Diego, California, United States
1004 Venture PartnersVenture Partner2024 — 2026San Francisco, California
VU Venture PartnersVenture Partner2024 — 2025San Francisco, California, United States
California Life Sciences (CLS)Member Board of Directors2018 — 2024San Francisco Bay Area
Procopio, Cory, Hargreaves & Savitch LLPChair, CEO Roundtable Connection - Life Sciences2023 — 2024Palo Alto, California, United States
ImmunogenXChief Business Officer2023 — 2024Newport Beach, California, United States
HistogenLead Independent Director, Audit and Scientific Committees2021 — 2024San Diego, California, United States
HistogenChairman Of The Board Of Directors2020 — 2021San Diego, California, United States
HistogenAudit Committee Chair; Governance and Compensation Committees2018 — 2021Greater San Diego Area
Venture InstituteVenture Member, Cohort 22023Palo Alto, California, United States
Association for Corporate Growth - ACG San DiegoChair, CEO Circle, Life Sciences and Healthcare2022 — 2023San Diego, California, United States
Lenire BiosciencesChief Executive Officer2021 — 2023San Diego, California, United States
Phoenix Molecular DesignsChairman, Independent Member, Board Of Directors2021 — 2022Vancouver, British Columbia, Canada
Objective Capital Partners, LLCSenior Advisor2021 — 2022
Objective Capital Partners, LLCManaging Director2015 — 2020Greater San Diego Area
Association for Corporate Growth - ACG San DiegoPresident, Board Of Directors2019 — 2021Greater San Diego Area
Amydis, Inc.Board Advisor2019 — 2021San Diego, California, United States
Amydis, Inc.Chief Business Officer2015 — 2019Greater San Diego Area
Talapo Therapeutics, Inc.Chief Executive Officer, Board of Directors2018 — 2020Greater San Diego Area
PermeaDerm, Inc.Board Advisor2017 — 2019Greater San Diego Area
Aqua Pharmaceuticals - an Almirall CompanyVice President, Corporate Development2010 — 2013Greater Philadelphia Area
AllerganSenior Director, Corporate Business Development2003 — 2010Irvine, CA
AllerganDirector, Project and Portfolio Management1998 — 2003Irvine, CA
Miravant Medical TechnologiesSenior Manager, Medical Research1993 — 1998Santa Barbara, CA
University of TorontoPost-Doctoral Research Fellowship1992 — 1993Toronto, Ontario CANADA
Roswell Park Cancer InstitutePost-Doctoral Research Fellowship1991 — 1992Buffalo, NY

Skills & more

Corporate DevelopmentBoard Governance7Strategic PartnershipsMergers & Acquisitions (M&A)2Business Valuation18Venture Financing4Capital FormationEntrepreneurship28Medical Diagnostics2EquitiesMedical Technology41Capital Markets38

+12 more

Venture ManagementPublic RelationsCorporate Venture CapitalInvestmentsValuationPortfolio ManagementStart-up VenturesPrivate EquityNegotiationMentoringEquity FinancingDebt Financing

Series 79 - Investment Banking Representative — FINRA
Series 63 - Uniform State Law Securities License — FINRA

From David's professional profile.

Deals · 1

HistogenBoard seat

via 1004 Venture Partners · filed Jul 2022 · $5M raise

Attribution from SEC filings, press coverage, and firm rosters.

Leave your own feedback

Network1

André ZimmermannScout

Partner at SHS Capital

Investors connected to David in public investor directories — a warm-intro map.

Frequently asked questions

Who is David H. Crean?: David H. Crean is Managing Partner of Cardiff Advisory LLC, an advisory firm serving life sciences and healthcare companies on mergers and acquisitions, licensing, valuations, and corporate strategy. He serves as Chief Business Officer of MediciNova (NASDAQ: MNOV), leading corporate development, partnering, investor relations, and capital markets strategy, and holds board positions including Chairman of Paracrine Inc. and Lead Independent Director of Cenna Biosciences. Over 30 years in life sciences and capital markets, Crean has advised more than 250 companies and completed more than 50 transactions exceeding $1 billion in aggregate value, with prior roles including Senior Director of Corporate Development at Allergan and Managing Director of Healthcare & Life Sciences at Objective Capital Partners.
What check size does David H. Crean write?: David H. Crean typically writes checks of $250K – $10M.
What boards does David H. Crean sit on?: David H. Crean holds tracked board seats at Histogen.
Where did David H. Crean go to school?: David H. Crean studied at University at Buffalo Pharmacy and Pharmaceutical Sciences (Doctor of Philosophy (Ph.D.), Biophysics); Pepperdine University (Master of Business Administration, Finance); University at Buffalo (Master of Science (M.S.), Natural Sciences / Oncology).